Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

[1] Neogi T(2011)Clinical practice: gout N Engl J Med 364 443-52

[2] Kuo CF(2015)Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study Ann Rheum Dis 74 661-7

[3] Grainge MJ(2008)Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II Arthritis Rheum 58 26-35

[4] Mallen C(2004)Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population J Rheumatol 31 1582-7

[5] Zhang W(2011)Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008 Arthritis Rheum 63 3136-41

[6] Doherty M(2015)Global epidemiology of gout: prevalence, incidence and risk factors Nat Rev Rheumatol 11 649-62

[7] Lawrence RC(2015)A systematic review of the economic and humanistic burden of gout Pharmacoeconomics 33 1029-47

[8] Felson DT(2007)British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout Rheumatology (Oxford) 46 1372-4

[9] Helmick CG(2012)2012 American College of Rheumatology guidelines for management of gout, part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis Arthritis Care Res 64 1447-61

[10] Arnold LM(2012)Adherence to EULAR recommendations for the treatment of gout [EULAR abstract FRI0397] Ann Rheum Dis 71 suppl 3 448-24

[1] Neogi T(2011)Clinical practice: gout N Engl J Med 364 443-52

[2] Kuo CF(2015)Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study Ann Rheum Dis 74 661-7

[3] Grainge MJ(2008)Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II Arthritis Rheum 58 26-35

[4] Mallen C(2004)Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population J Rheumatol 31 1582-7

[5] Zhang W(2011)Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008 Arthritis Rheum 63 3136-41

[6] Doherty M(2015)Global epidemiology of gout: prevalence, incidence and risk factors Nat Rev Rheumatol 11 649-62

[7] Lawrence RC(2015)A systematic review of the economic and humanistic burden of gout Pharmacoeconomics 33 1029-47

[8] Felson DT(2007)British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout Rheumatology (Oxford) 46 1372-4

[9] Helmick CG(2012)2012 American College of Rheumatology guidelines for management of gout, part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis Arthritis Care Res 64 1447-61

[10] Arnold LM(2012)Adherence to EULAR recommendations for the treatment of gout [EULAR abstract FRI0397] Ann Rheum Dis 71 suppl 3 448-24